## **Prior Authorization Request Form for**

brigatinib (Alunbrig), alectinib (Alecensa), and ceritinib (Zykadia)



## JOHNS HOPKINS HEALTHCARE

7231 Parkway Drive, Suite 100, Hanover, MD 21076

FAX Completed Form and Applicable Progress Notes to: (410) 424-4037

## **USFHP Pharmacy Prior Authorization Form**

To be completed by Requesting provider		
Drug Name:	Strength:	
Dosage/Frequency (SIG):	Duration of Therapy:	

Questions? Contact the Pharmacy Dept at: (888) 819-1043, option 4

Clinical Documentation must accompany form in order for a determination to be made.

Step 1	Please complete patient and physician information (please to the patient Name:  Address:	ease print):  nysician Name:  Address:			
	Sponsor ID #  Date of Birth:	Phone #:			
Step	Please complete the clinical assessment:				
2	Is the requested medication being prescribed by or in consultation with a hematologist or oncologist?	☐ Yes Proceed to question 2	□ No STOP Coverage not approved		
	2. Does the patient have a documented diagnosis of metastatic non-small cell lung cancer (NSCLC)?	☐ Yes Proceed to question 3	☐ No Proceed to question <b>4</b>		
	Is the NSCLC anaplastic lymphoma kinase (ALK) positive as detected by an FDA-approved test?	☐ Yes Sign and date below	☐ No STOP Coverage not approved		
	4. Please provide the diagnosis.	Proceed to question <b>5</b>			
	5. Is the diagnosis cited in the National Comprehensive Cancer Network (NCCN) guidelines as a category 1, 2A, or 2B recommendation?	☐ Yes Sign and date below	□ No STOP		
			Coverage not approved		

## **Prior Authorization Request Form for**

brigatinib (Alunbrig), alectinib (Alecensa), and ceritinib (Zykadia)

Step 3	I certify the above is true to the best of my knowled	ge. Please sign and date:	
	Prescriber Signature	Date	
			[29 January 2020]
For Intern	nal Use Only		
Approv	ed:	Duration of Approval:	month(s)
Denied	:	Authorized By:	
Incomp	olete/Other:	PA#:	
Date Faxe	ed to MD:	Date Decision Rendered	•